Executive readout · one minute
Call research workspace
Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.
SMMT
$16.80
-0.65%
SMMT
· Summit Therapeutics Inc.
$16.80
-0.11 (-0.65%)
At close · Oct 1
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jul 23, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Jul 23, 2026
Market Cap
$12.45B
Shares
797.75M
Volume · Sep 30
13.06M
Avg daily vol (3M)
5.57M
All earnings calls
Earnings call · FY2024 Q2
Summit Therapeutics Inc. (SMMT) Q2 2024 Earnings Call
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Diluted EPS
-$0.09
Net income
-$60.38M
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed Aug 6, 2024 · complete as-filed document
SEC periodic report
10-Q report
Filed Aug 6, 2024 · complete as-filed document